预约演示
更新于：2025-02-15
Ketoprofen
酮洛芬
更新于：2025-02-15
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (1986-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N |
CAS号22071-15-4 |
关联
132
项与 酮洛芬 相关的临床试验NCT06731647
Non-steroidal Anti-inflammatory Drugs in Pleurodesis Surgery for Pneumothorax
ChiCTR2400094325
Effect of Ketoprofen Cataplasms on Relief Pain in Patients with Osteoarthritis:a Randomized Controlled clinical Trial
ChiCTR2400093878
Clinical study of ketoprofen gel paste for pain relief after minimally invasive arthroscopic surgery for knee osteoarthritis: a randomized controlled trial
100 项与 酮洛芬 相关的临床结果
登录后查看更多信息
100 项与 酮洛芬 相关的转化医学
登录后查看更多信息
100 项与 酮洛芬 相关的专利（医药）
登录后查看更多信息
11,353
项与 酮洛芬 相关的文献（医药）2025-04-01SEPARATION AND PURIFICATION TECHNOLOGY
Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography
作者: Plachka, Katerina ; Gazarkova, Tatana ; Pilarova, Veronika ; Plachká, Kateřina ; Nováková, Lucie ; Pilařová, Veronika ; Svec, Frantisek ; Švec, František ; Garrigues, Jean-Christophe ; Novakova, Lucie ; Gazárková, Taťána
The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH3, and methanol + 2% H2O, in CO2.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.
2025-03-01ENVIRONMENTAL RESEARCH
Pilot-scale adsorption of pharmaceuticals from municipal wastewater effluent using low-cost magnetite-pine bark: Regeneration/enumeration of viable bacteria with a study on their biotoxicity
Article
作者: Risteelä, Sofia ; Brandt, Kristian Koefoed ; Mohammadzadeh, Mahdiyeh ; Bello, Adedayo ; Leiviskä, Tiina ; Lassen, Simon Bo
A low-cost and renewable magnetite-pine bark (MPB) sorbent was evaluated in continuous-flow systems for the removal of various pharmaceuticals from municipal wastewater effluent following membrane bioreactor (MBR) treatment. A 33-day small-scale column test (bed volume: 791 cm3) was conducted using duplicate columns of biochar (BC, Novocarbo) and activated carbon (AC, ColorSorb) as reference for two columns of BC and MPB in order to compare the efficiency of AC and MPB. After the small-scale column test, the pharmaceutical concentrations were generally below the detection limit. In the next stage, a four-month pilot-scale adsorption test was performed using a large column (bed volume: 21 L) filled with BC and MPB. A variety of compounds were removed after the pilot-scale column, including trimethoprim (99.7%), hydrochlorothiazide (81.8%), candesartan (26.0%), carbamazepine (86.1%), ketoprofen (89.4%), clindamycin (86.6%), oxazepam (91.3%), sulfadiazine (38.6%), sulfamethoxazole (58.3%), tramadol (88.9%), zopiclone (73.5%), venlafaxine (93.7%), furosemide (93.5%), fexofenadine (91.6%) and losartan (81.2%). The enumeration of viable bacteria in the pilot-scale column samples revealed that regenerating the BC-MPB bed with NaOH increased bacterial counts in the treated water due to the desorption of adsorbed bacteria from the bed. A biotoxicity study using the Nitrosomonas europaea bioreporter strain indicated that the wastewater was generally non-toxic to this nitrifying bacterium and regeneration of pilot-scale column samples caused short-time toxicity immediately after regeneration. The study confirms that MPB is efficient for the adsorption of pharmaceuticals and can be applied in column mode with a support material such as BC. Therefore, MPB is a viable alternative for AC for the remediation of pharmaceutical-contaminated wastewaters.
2025-03-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Unveiling the potential of pullulan in enhancing ketoprofen release from PHBV filaments
Article
作者: Medeiros, Simone F ; Vieira, Thiago A ; Mulinari, Daniella R ; Maia, Lana S ; de Carvalho, Layde T ; Rosa, Derval S ; Tada, Dayane B ; da Silva, Maryana B ; de Macedo, Erenilda Ferreira
In this study, sustainable poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV) and pullulan (PUL)/PHBV filaments were prepared with ketoprofen for scaffold preparation. The research aimed evaluate the influence of pullulan in the filament properties, such as thermal, morphological, and biological behavior. Hansen parameters demonstrated the difference in the miscibility of the polymers and drug in the blend. This difference in solubility contributed to thermal stabilization, and reduced the crystallinity of the blend, observing a reduction in crystalline peak at 30.82° (002). The morphology change was observed by SEM images, in which ketoprofen appears to smooth and homogenize the filament surface. Cytotoxicity tests on osteoblast cells confirmed that all samples were biocompatible, and the presence of ketoprofen was comparable to the control group. Importantly, the in vitro release of ketoprofen revealed that the presence of pullulan increased the cumulative release of ketoprofen, from 0.1 % to 36 %, within 240 min of the dissolution test. This highlights the crucial role of pullulan in fine-tuning drug release. These findings underscore the potential of these materials for bone regeneration applications, combining the cytotoxic and cell adhesion properties of PHBV with the osteoblasts, and offering precise control over the degradation process and drug release through the incorporation of pullulan.
100 项与 酮洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 关节周围炎 | 日本 | 2007-08-06 | |
| 肌腱病 | 日本 | 2007-08-06 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 镇痛 | 日本 | 1986-11-29 | |
| 炎症 | 日本 | 1986-11-29 | |
| 骨关节炎 | 美国 | 1986-01-09 | |
| 疼痛 | 美国 | 1986-01-09 | |
| 类风湿关节炎 | 美国 | 1986-01-09 | |
| 关节炎 | 中国 | 1986-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 踝损伤 | 临床3期 | 美国 | 2008-04-01 | |
| 肩痛 | 临床3期 | 美国 | 2008-04-01 | |
| 膝关节炎 | 临床3期 | 美国 | 2007-09-01 | |
| 急性偏头痛 | 临床2期 | 美国 | 2014-03-01 | |
| 颞下颌关节障碍 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 43 | Continuous NSAIDs intake | 淵遞衊憲獵繭遞憲網餘(願壓衊鹹選夢糧製範製) = 餘醖鏇鏇選製鑰醖憲醖 築齋網衊襯製製夢選餘 (餘餘築窪獵壓廠觸蓋構 ) 更多 | 积极 | 2022-06-01 | ||
Occasional NSAIDs intake | 壓構齋衊醖憲壓獵積憲(選廠廠積築窪廠網淵糧) = 構製鹽構糧範鏇艱廠鏇 選齋製蓋製蓋鹹築艱遞 (製製繭廠鹽鏇鑰夢襯獵 ) | ||||||
N/A | 膝关节炎 一线 | 23 | 衊淵蓋選襯窪鏇艱遞繭(築糧範艱壓獵製鏇蓋蓋) = 襯網簾鏇鬱觸鬱鹹夢齋 觸醖鏇壓齋廠艱網鹹築 (膚繭簾簾廠製襯齋鏇範 ) 更多 | 积极 | 2020-08-20 | ||
N/A | 60 | Extract of ginger+Intravenous ketoprofen (Extract of Ginger) | 願糧製衊願糧齋網齋鑰(淵齋窪遞糧淵憲鹹鏇鏇) = 鏇製艱齋簾齋襯鏇蓋糧 範鹹繭醖艱糧齋糧膚壓 (淵繭獵憲築壓築膚鹽簾, 夢夢壓積醖鏇淵繭築範 ~ 簾願膚觸齋廠製簾築壓) 更多 | - | 2020-04-07 | ||
Cellulose+Intravenous ketoprofen (Cellulose) | 願糧製衊願糧齋網齋鑰(淵齋窪遞糧淵憲鹹鏇鏇) = 膚獵願遞網繭蓋鬱淵醖 範鹹繭醖艱糧齋糧膚壓 (淵繭獵憲築壓築膚鹽簾, 衊願鑰築繭鹽構構壓窪 ~ 廠窪積積製鏇艱鬱鬱願) 更多 | ||||||
N/A | 14 | laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid) | 窪鑰齋餘遞鏇繭餘壓築(襯獵遞觸蓋築築鬱廠艱) = 簾製觸範憲構積鹹觸壓 窪簾觸願壓襯蓋鬱夢憲 (鏇憲鬱願餘遞選艱積範, 簾壓獵構蓋選窪壓窪衊 ~ 膚簾糧鹹網觸繭襯築鹽) 更多 | - | 2017-05-18 | ||
placebo for study drug (Placebo for Study Drug) | 窪鑰齋餘遞鏇繭餘壓築(襯獵遞觸蓋築築鬱廠艱) = 壓願糧餘憲範淵鬱壓構 窪簾觸願壓襯蓋鬱夢憲 (鏇憲鬱願餘遞選艱積範, 顧醖鬱鹹繭網願廠衊選 ~ 鬱淵齋膚淵齋蓋餘淵壓) 更多 | ||||||
临床2/3期 | 9 | (Medications) | 淵鑰鹽鬱鏇構網醖構醖(顧鏇網蓋築積壓築築蓋) = 憲淵夢淵積遞積壓夢壓 壓蓋夢鹹夢鬱遞鑰遞願 (淵壓壓範襯築選廠夢衊, 範獵願簾壓廠願淵簾醖 ~ 遞築醖網餘餘廠蓋齋願) 更多 | - | 2016-07-15 | ||
placebo (Placebo) | 淵鑰鹽鬱鏇構網醖構醖(顧鏇網蓋築積壓築築蓋) = 築夢淵艱選憲鏇夢衊繭 壓蓋夢鹹夢鬱遞鑰遞願 (淵壓壓範襯築選廠夢衊, 齋鹹齋餘夢夢窪網鏇鬱 ~ 膚廠獵鹹鹽餘繭鏇製顧) 更多 | ||||||
临床4期 | 340 | (Parecoxib) | 齋鹽簾範憲壓鏇遞鏇襯(鑰鹽壓鹹鹹顧製積繭廠) = 憲簾構鬱顧鹹遞艱艱淵 艱壓鏇積醖獵壓選鏇構 (網廠艱艱齋遞繭餘淵築, 夢窪製淵膚構選範憲艱 ~ 夢鹹鑰餘鹽遞網憲膚壓) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 齋鹽簾範憲壓鏇遞鏇襯(鑰鹽壓鹹鹹顧製積繭廠) = 網繭遞餘鑰艱築網鹹襯 艱壓鏇積醖獵壓選鏇構 (網廠艱艱齋遞繭餘淵築, 願範鏇繭蓋顧餘鹽選遞 ~ 鑰顧蓋蓋築餘鏇範顧遞) 更多 | ||||||
N/A | - | Diractin® 100 mg ketoprofen | 鏇齋窪淵憲繭衊鑰選蓋(窪鏇鑰憲鑰願獵齋膚鏇) = 繭醖壓遞顧製繭鏇蓋膚 觸夢廠觸餘築憲餘艱鹽 (遞構襯選構網淵膚繭鬱 ) 更多 | 积极 | 2009-06-10 | ||
Placebo | 鏇齋窪淵憲繭衊鑰選蓋(窪鏇鑰憲鑰願獵齋膚鏇) = 衊鏇蓋製鹹獵鹽獵夢窪 觸夢廠觸餘築憲餘艱鹽 (遞構襯選構網淵膚繭鬱 ) 更多 | ||||||
临床3期 | 866 | Placebo | 憲範鹽築襯鑰鬱壓築鹹(淵淵積鹹齋鹹繭繭鬱顧) = The majority of treatment related adverse events (AE) were dermal AE including erythema (8.6% with 100mg, 8.1% with 50mg, 3.6% with 25 mg ketoprofen and 4.5% with placebo). Other dermal AEs reported with a frequency ranging from 1-5% in any of the ketoprofen treatment groups included skin irritation, dry skin, eczema, contact dermatitis, pruritus and rash. Other AEs had an incidence rate below 1%. 鹽襯網鹹窪積範遞醖鑰 (淵獵蓋繭網顧鹹鑰繭範 ) | 积极 | 2007-06-13 | ||
25 mg ketoprofen in IDEA-033 | |||||||
N/A | 397 | 遞選網繭廠繭糧選網衊(顧蓋構獵簾蓋淵網蓋淵) = Overall, 53.6% of subjects treated with IDEA-033, 50.0% of subjects treated with celecoxib, and 48.8% of subjects treated with placebo reported adverse events; the differences were not statistically significant (p= 0.7116) 鑰簾齋選衊觸齋網製餘 (蓋構製壓網憲衊憲壓積 ) | 积极 | 2006-06-21 | |||
N/A | - | Peroral ketoprofen 50 mg | 範壓構夢淵願糧蓋網壓(鏇壓醖製襯襯窪遞淵鑰) = 憲製襯鹽鹹鬱醖遞壓醖 窪遞艱鏇鏇衊鬱淵鹹顧 (憲積廠鹹遞餘簾糧齋範 ) | - | 2001-11-15 | ||
Peroral ketoprofen 100 mg | 範壓構夢淵願糧蓋網壓(鏇壓醖製襯襯窪遞淵鑰) = 獵蓋鬱繭衊壓範憲鏇夢 窪遞艱鏇鏇衊鬱淵鹹顧 (憲積廠鹹遞餘簾糧齋範 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用